JP2009502961A - 新規な医薬組成物 - Google Patents

新規な医薬組成物 Download PDF

Info

Publication number
JP2009502961A
JP2009502961A JP2008524206A JP2008524206A JP2009502961A JP 2009502961 A JP2009502961 A JP 2009502961A JP 2008524206 A JP2008524206 A JP 2008524206A JP 2008524206 A JP2008524206 A JP 2008524206A JP 2009502961 A JP2009502961 A JP 2009502961A
Authority
JP
Japan
Prior art keywords
compound
deuterium
prodrug
useful
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502961A5 (https=
Inventor
ロジャー タン
Original Assignee
コンサート ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンサート ファーマシューティカルズ インコーポレイテッド filed Critical コンサート ファーマシューティカルズ インコーポレイテッド
Publication of JP2009502961A publication Critical patent/JP2009502961A/ja
Publication of JP2009502961A5 publication Critical patent/JP2009502961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008524206A 2005-07-29 2006-07-28 新規な医薬組成物 Pending JP2009502961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70357005P 2005-07-29 2005-07-29
US70361205P 2005-07-29 2005-07-29
PCT/US2006/029461 WO2007016361A2 (en) 2005-07-29 2006-07-28 Novel pharmaceutical compounds

Publications (2)

Publication Number Publication Date
JP2009502961A true JP2009502961A (ja) 2009-01-29
JP2009502961A5 JP2009502961A5 (https=) 2009-09-10

Family

ID=37709213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524206A Pending JP2009502961A (ja) 2005-07-29 2006-07-28 新規な医薬組成物

Country Status (8)

Country Link
US (1) US20070037815A1 (https=)
EP (2) EP2324886A1 (https=)
JP (1) JP2009502961A (https=)
KR (1) KR20080047375A (https=)
AU (1) AU2006275702A1 (https=)
BR (1) BRPI0615972A2 (https=)
CA (1) CA2616366A1 (https=)
WO (1) WO2007016361A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531433A (ja) * 2009-06-25 2012-12-10 メドリューション リミテッド キナーゼ阻害剤としての置換複素環式化合物とその用法
JP2018517720A (ja) * 2015-06-26 2018-07-05 重▲慶▼文理学院 新規ホスホジエステラーゼ５阻害剤とその使用
JP2019506441A (ja) * 2016-02-28 2019-03-07 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． 置換ヘテロアリール化合物、該化合物を含む組成物およびその使用
JP2021515010A (ja) * 2018-02-28 2021-06-17 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
JP2010507593A (ja) 2006-10-20 2010-03-11 コンサート ファーマシューティカルズ インコーポレイテッド ３−（ジヒドロ−１Ｈ−ピラゾロ［４，３−ｄ］ピリミジン−５−イル）−４−プロポキシベンゼンスルホンアミド誘導体および使用方法
WO2008088727A2 (en) * 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
US20080319086A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched salmeterol
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
WO2009099620A1 (en) * 2008-02-04 2009-08-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2687854A1 (en) * 2012-07-19 2014-01-22 Chiron AS Test kit for the quantitative determination of narcotic drugs
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
HK1220184A1 (zh) 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CA2945609C (en) 2014-07-29 2023-05-23 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
JP6969800B2 (ja) 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
AU2016406709C1 (en) 2016-05-10 2023-04-27 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
EP3675860B1 (en) 2017-08-28 2023-03-08 Zhihong, Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
WO2019099651A1 (en) * 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Methods of using deuterated pyruvate kinase activators
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
EP3856742B1 (en) 2018-11-01 2024-10-02 Lynk Pharmaceuticals Co. Ltd. Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
WO2020118683A1 (en) 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
WO2020146845A1 (en) 2019-01-11 2020-07-16 University Of Rochester Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a
WO2020160054A1 (en) 2019-02-01 2020-08-06 Canwell Biotech Limited Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
CN114616234B (zh) 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
EP4034119A4 (en) * 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
AU2020356955A1 (en) 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
WO2021216325A1 (en) 2020-04-22 2021-10-28 University Of Rochester Compositions and methods for treating metabolic and cardiovascular diseases
JP2024506999A (ja) 2021-02-02 2024-02-15 コン，ヤンピン がんを処置するための組成物および方法
WO2022271861A1 (en) 2021-06-22 2022-12-29 Dana-Farber Cancer Institute, Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors
WO2025126109A1 (en) 2023-12-15 2025-06-19 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110099A (en) 1975-12-17 1978-08-29 Eli Lilly And Company Novel fluoroalkoxyphenyl-substituted nitrogen heterocycles
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
IT1291320B1 (it) 1997-05-08 1999-01-07 Borregaard Italia Spa Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US20040063719A1 (en) 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CA2365782A1 (en) 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US7737147B2 (en) 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6892568B2 (en) 2003-02-03 2005-05-17 Honda Giken Kogyo Kabushiki Kaisha Noise detection system and method
WO2002072145A1 (en) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
EP1383765B1 (en) * 2001-04-25 2006-12-13 Lilly Icos LLC Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
LV12979B (en) 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US20050107394A1 (en) 2001-12-17 2005-05-19 Ardeschir Ghofrani Novel use of selective pde5 inhibitors
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US20030235609A1 (en) 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US7091207B2 (en) 2002-05-22 2006-08-15 Virginia Commonwealth University Method of treating myocardial infarction with PDE-5 inhibitors
US20040077624A1 (en) 2002-05-23 2004-04-22 Pfizer Inc. Novel combination
US20040132731A1 (en) 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US20050070969A1 (en) 2002-09-06 2005-03-31 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation and the delivery of drugs to the sacral and pudendal nerves
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
US7369894B2 (en) 2002-09-06 2008-05-06 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US8133903B2 (en) 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
US20040180958A1 (en) 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
GB0230025D0 (en) 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
WO2004069167A2 (en) 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
JP4533590B2 (ja) 2003-02-28 2010-09-01 ファイザー株式会社 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
WO2004078717A1 (en) 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
PA8597401A1 (es) 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
CA2528975A1 (en) 2003-06-10 2004-12-16 Pfizer Inc. Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US7745630B2 (en) * 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005065308A2 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531433A (ja) * 2009-06-25 2012-12-10 メドリューション リミテッド キナーゼ阻害剤としての置換複素環式化合物とその用法
JP2018517720A (ja) * 2015-06-26 2018-07-05 重▲慶▼文理学院 新規ホスホジエステラーゼ５阻害剤とその使用
JP2019506441A (ja) * 2016-02-28 2019-03-07 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． 置換ヘテロアリール化合物、該化合物を含む組成物およびその使用
US10479767B2 (en) 2016-02-28 2019-11-19 Shenzhen Targetrx, Inc. Substituted heteroaryl compound, composition containing same, and application thereof
US10851062B2 (en) 2016-02-28 2020-12-01 Shenzhen Targetrx, Inc. Substituted heteroaryl compound, composition containing same, and application thereof
JP2021515010A (ja) * 2018-02-28 2021-06-17 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法
JP7348906B2 (ja) 2018-02-28 2023-09-21 フェロ セラピューティクス， インコーポレイテッド フェロトーシス誘導活性を有する化合物およびそれらの使用方法

Also Published As

Publication number Publication date
EP1909576A4 (en) 2010-09-01
AU2006275702A1 (en) 2007-02-08
EP2324886A1 (en) 2011-05-25
BRPI0615972A2 (pt) 2011-05-31
CA2616366A1 (en) 2007-02-08
WO2007016361A2 (en) 2007-02-08
EP1909576A2 (en) 2008-04-16
KR20080047375A (ko) 2008-05-28
US20070037815A1 (en) 2007-02-15
WO2007016361A3 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
US7863274B2 (en) Deuterium enriched analogues of tadalafil as PDE5 inhibitors
JP2009502961A (ja) 新規な医薬組成物
JP5301991B2 (ja) 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
JP5647519B2 (ja) 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
US20080033011A1 (en) Novel benzo[d][1,3]-dioxol derivatives
US20040220186A1 (en) PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
KR102221201B1 (ko) 치환된 바이사이클릭 디하이드로피리미디논 및 호중구 엘라스타제 활성의 억제제로서의 이의 용도
KR20150037950A (ko) 4-메틸-2,3,5,9,9ｂ-펜타아자-사이클로펜타[ａ]나프탈렌
EP1534707B9 (en) Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
WO2016016365A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
Jiang et al. Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors
KR20180043289A (ko) 화합물
EP1101765A2 (fr) Nouveaux composés analogues de la camptothécine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN101277613A (zh) 新颖医药化合物
HK1117532B (en) Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130226